WO2011039734A3 - Use of genes involved in anchorage independence for the optimization of diagnosis and treatment of human cancer - Google Patents

Use of genes involved in anchorage independence for the optimization of diagnosis and treatment of human cancer Download PDF

Info

Publication number
WO2011039734A3
WO2011039734A3 PCT/IB2010/054470 IB2010054470W WO2011039734A3 WO 2011039734 A3 WO2011039734 A3 WO 2011039734A3 IB 2010054470 W IB2010054470 W IB 2010054470W WO 2011039734 A3 WO2011039734 A3 WO 2011039734A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
diagnosis
optimization
anchorage independence
human cancer
Prior art date
Application number
PCT/IB2010/054470
Other languages
French (fr)
Other versions
WO2011039734A2 (en
Inventor
Enzo Medico
Claudio Isella
Alessia Mira
Original Assignee
Enzo Medico
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzo Medico filed Critical Enzo Medico
Publication of WO2011039734A2 publication Critical patent/WO2011039734A2/en
Publication of WO2011039734A3 publication Critical patent/WO2011039734A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Abstract

The present invention discloses identification of GAB2-driven processes and anchorage independence associated with diagnosis, prognosis, metastasis, metastatic relapse, metastatic potential and prediction of response to treatment of cancers. In particular, a GAB2-signature based on anchorage independence is identified which can serve to define processes relevant to progression and response to treatment of human cancers.
PCT/IB2010/054470 2009-10-02 2010-10-04 Use of genes involved in anchorage independence for the optimization of diagnosis and treatment of human cancer WO2011039734A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24796709P 2009-10-02 2009-10-02
US61/247,967 2009-10-02

Publications (2)

Publication Number Publication Date
WO2011039734A2 WO2011039734A2 (en) 2011-04-07
WO2011039734A3 true WO2011039734A3 (en) 2012-02-23

Family

ID=43826728

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/054470 WO2011039734A2 (en) 2009-10-02 2010-10-04 Use of genes involved in anchorage independence for the optimization of diagnosis and treatment of human cancer

Country Status (1)

Country Link
WO (1) WO2011039734A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906864B2 (en) 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
BRPI0913578A2 (en) 2008-05-14 2017-06-06 Dermtech Int diagnosis of melanoma and solar lentigo by nucleic acid analysis
SG181563A1 (en) 2009-12-08 2012-07-30 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
EP2913405B1 (en) 2010-07-27 2016-11-09 Genomic Health, Inc. Method for using gene expression to determine prognosis of prostate cancer
JP2015503330A (en) * 2011-12-22 2015-02-02 アベオ ファーマシューティカルズ， インコーポレイテッド Identification of multigene biomarkers
MY176695A (en) 2012-01-27 2020-08-19 Abbvie Inc Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
CN102707058B (en) * 2012-05-30 2014-09-24 山东大学 Tumor necrosis factor-alpha induced protein 8 L3 (TIPE3) immunohistochemistry detection kit for diagnosing lung cancer
US20140272986A1 (en) 2013-03-14 2014-09-18 Castle Biosciences, Inc. Diagnostic test for predicting metastasis and recurrence in cutaneous melanoma
EP3798316A3 (en) * 2013-03-15 2021-06-09 Myriad Genetics, Inc. Genes and gene signatures for diagnosis and treatment of melanoma
US20140314792A1 (en) * 2013-03-15 2014-10-23 Institució Catalana De Recerca I Estudis Avançats Method for the diagnosis, prognosis and treatment of cancer metastasis
CN106061501A (en) 2013-12-29 2016-10-26 Cl昂科莱吉有限公司 Methods and compositions relating to p62/sqstm1 for the treatment and prevention of inflammation-associated diseases
JP6711968B2 (en) * 2014-01-10 2020-06-17 学校法人順天堂 Evaluation method of lymph node metastasis of endometrial cancer
ES2946681T3 (en) 2014-07-02 2023-07-24 Myriad Mypath Llc Genes and gene signatures for the diagnosis and treatment of melanoma
CA2967224C (en) 2014-12-11 2023-08-22 Inbiomotion S.L. Binding members for human c-maf
CN111402954B (en) * 2019-01-02 2023-07-21 中国人民解放军军事科学院军事医学研究院 Method for identifying and predicting human genes related to space radiation injury protection drug targets
CA3134936A1 (en) 2019-03-26 2020-10-01 Dermtech, Inc. Novel gene classifiers and uses thereof in skin cancers

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050196767A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
EP1666595A1 (en) * 2000-10-26 2006-06-07 Beth Israel Deaconess Medical Center, Inc. GAB2 (P97) gene and methods of use thereof
WO2006060653A2 (en) * 2004-11-30 2006-06-08 Veridex Llc Lung cancer prognostics
WO2008094678A2 (en) * 2007-01-31 2008-08-07 Applera Corporation A molecular prognostic signature for predicting breast cancer distant metastasis, and uses thereof
US20090123924A1 (en) * 2005-07-07 2009-05-14 Biomerieux Method for Breast Cancer Diagnosis
WO2009083780A1 (en) * 2007-12-28 2009-07-09 Ipsogen Breast cancer expresion profiling

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1666595A1 (en) * 2000-10-26 2006-06-07 Beth Israel Deaconess Medical Center, Inc. GAB2 (P97) gene and methods of use thereof
US20050196767A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
WO2006060653A2 (en) * 2004-11-30 2006-06-08 Veridex Llc Lung cancer prognostics
US20090123924A1 (en) * 2005-07-07 2009-05-14 Biomerieux Method for Breast Cancer Diagnosis
WO2008094678A2 (en) * 2007-01-31 2008-08-07 Applera Corporation A molecular prognostic signature for predicting breast cancer distant metastasis, and uses thereof
WO2009083780A1 (en) * 2007-12-28 2009-07-09 Ipsogen Breast cancer expresion profiling

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
"SnagIt from SnagIt from document properties of http://dott-scsv.campusnet.unito.it/tesi/mira_thesis.pdf", 12 November 2007 (2007-11-12) - 19 July 2011 (2011-07-19), XP002652529, Retrieved from the Internet <URL:http://dott-scsv.campusnet.unito.it/tesi/mira_thesis.pdf> [retrieved on 20110719] *
"Webtable 2: Genes associated with metagene predictors of lymph-node metastasis", THE LANCET, LANCET LIMITED. LONDON, GB, 10 May 2003 (2003-05-10), XP002652530, Retrieved from the Internet <URL:http://image.thelancet.com/extras/02art11142webtable2.pdf> [retrieved on 20110720] *
A MIRA ET AL: "The GAB2 signaling scaffold promotes anchorage independence and drives a transcriptional response associated with metastatic progression of breast cancer", ONCOGENE, vol. 28, no. 50, 17 December 2009 (2009-12-17), pages 4444 - 4455, XP055003067, ISSN: 0950-9232, DOI: 10.1038/onc.2009.296 *
ANONYMOUS: "Archivio delle tesi del dottorato, 2007 - Ciclo XX - 2010 - Ciclo XXIII", 2 May 2011 (2011-05-02), XP002652526, Retrieved from the Internet <URL:http://dott-scsv.campusnet.unito.it/do/home.pl/View?doc=archivio_tesi.html> [retrieved on 20110719] *
BENTIRES-ALJ M ET AL: "A role for the scaffolding adapter GAB2 in breast cancer", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 12, no. 1, 20 December 2005 (2005-12-20), pages 114 - 121, XP002374003, ISSN: 1078-8956, DOI: 10.1038/NM1341 *
C. DESMEDT ET AL: "Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series", CLINICAL CANCER RESEARCH, vol. 13, no. 11, 1 June 2007 (2007-06-01), pages 3207 - 3214, XP055003155, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-06-2765 *
CHRISTOS SOTIRIOU ET AL: "Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?", NATURE REVIEWS CANCER, vol. 7, no. 7, 1 July 2007 (2007-07-01), pages 545 - 553, XP055003315, ISSN: 1474-175X, DOI: 10.1038/nrc2173 *
DALY R J ET AL: "The docking protein Gab2 is overexpressed and estrogen regulated in human breast cancer", ONCOGENE, NATURE PUBLISHING GROUP, GB, vol. 21, no. 33, 1 August 2002 (2002-08-01), pages 5175 - 5181, XP002374002, ISSN: 0950-9232, DOI: 10.1038/SJ.ONC.1205522 *
HUANG E ET AL: "Gene expression predictors of breast cancer outcomes", THE LANCET, LANCET LIMITED. LONDON, GB, vol. 361, no. 9369, 10 May 2003 (2003-05-10), pages 1590 - 1596, XP004782813, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(03)13308-9 *
HUANG F ET AL: "Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: Rationale for patient selection", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER REREARCH, US, vol. 67, no. 5, 1 March 2007 (2007-03-01), pages 2226 - 2238, XP002558115, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-06-3633 *
ISELLA CLAUDIO: "Genomic signatures of cancer progression:from in vitro experimental models toprediction of human breast cancer outcome", 17 November 2008 (2008-11-17), UNIVERSITA DEGLI STUDI DI TORINODIPARTIMENTO DI SCIENZE BIOMEDICHE, XP002652525, Retrieved from the Internet <URL:http://dott-scsv.campusnet.unito.it/tesi/isella_thesis.pdf> [retrieved on 20110719] *
K. A. CHERNOFF ET AL: "GAB2 Amplifications Refine Molecular Classification of Melanoma", CLINICAL CANCER RESEARCH, vol. 15, no. 13, 1 July 2009 (2009-07-01), pages 4288 - 4291, XP055003249, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-09-0280 *
LEE SUNG HAK ET AL: "Increased expression of Gab2, a scaffolding adaptor of the tyrosine kinase signalling, in gastric carcinomas", PATHOLOGY, MODERN MEDICINE, SYDNEY, AU, vol. 39, no. 3, 1 January 2007 (2007-01-01), pages 326 - 329, XP009150449, ISSN: 0031-3025 *
MILLER L D ET AL: "An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, WASHINGTON, DC; US, vol. 102, no. 38, 20 September 2005 (2005-09-20), pages 13550 - 13555, XP003019005, ISSN: 0027-8424, DOI: 10.1073/PNAS.0506230102 *
MIRA ALESSIA: "Functional screening for genes conferring anchorage-independence to human immortalized breast cells", 12 November 2007 (2007-11-12), UNIVERSITA' DEGLI STUDI DI TORINODIPARTIMENTO DI SCIENZE BIOMEDICHE, XP002652528, Retrieved from the Internet <URL:http://dott-scsv.campusnet.unito.it/tesi/mira_thesis.pdf> [retrieved on 20110719] *
SNAGIT FROM DOCUMENT PROPERTIES OF HTTP://DOTT-SCSV.CAMPUSNET.UNITO.IT/TESI/ISELLA_THESIS.PDF, 17 November 2008 (2008-11-17), XP002652527, Retrieved from the Internet <URL:http://dott-scsv.campusnet.unito.it/tesi/isella_thesis.pdf> [retrieved on 20110719] *
SORLIE T ET AL: "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, WASHINGTON, DC; US, vol. 98, no. 19, 11 September 2001 (2001-09-11), pages 10869 - 10874, XP002215483, ISSN: 0027-8424, DOI: 10.1073/PNAS.191367098 *
SOTIRIOU CHRISTOS ET AL: "Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis", NATIONAL CANCER INSTITUTE. JOURNAL (ONLINE), OXFORD UNIVERSITY PRESS, GB, vol. 98, no. 4, 15 February 2006 (2006-02-15), pages 262 - 272, XP002490627, ISSN: 1460-2105, DOI: 10.1093/JNCI/DJJ052 *
VAN 'T VEER L J ET AL: "Gene expression profiling predicts clinical outcome of breast cancer", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 415, 31 January 2002 (2002-01-31), pages 530 - 536, XP002967258, ISSN: 0028-0836, DOI: 10.1038/415530A *
VIJVER VAN DE M J ET AL: "A GENE-EXPRESSION SIGNATURE AS A PREDICTOR OF SURVIVAL IN BREAST CANCER", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 347, no. 25, 19 December 2002 (2002-12-19), pages 1999 - 2009, XP008032093, ISSN: 1533-4406, DOI: 10.1056/NEJMOA021967 *
WANG Y ET AL: "Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer", THE LANCET, LANCET LIMITED. LONDON, GB, vol. 365, no. 9460, 19 February 2005 (2005-02-19), pages 671 - 679, XP025276532, ISSN: 0140-6736, [retrieved on 20050219] *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof

Also Published As

Publication number Publication date
WO2011039734A2 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
WO2011039734A3 (en) Use of genes involved in anchorage independence for the optimization of diagnosis and treatment of human cancer
WO2010017515A3 (en) Breast cancer specific markers and methods of use
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
WO2009158620A3 (en) Signatures and determinants associated with metastasis methods of use thereof
WO2008104543A3 (en) Method for predicting the occurrence of metastasis in breast cancer patients
WO2012083969A3 (en) Microrna for diagnosis of pancreatic cancer
WO2012021887A3 (en) Biomarkers for the early detection of breast cancer
EP2257647A4 (en) MicroRNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF GASTRIC CANCER
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
WO2011085263A3 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
WO2009094647A3 (en) P53 biomarkers
MX2013002084A (en) Biomarkers and methods of treatment.
ZA201300519B (en) Novel antibody for the diagnosis and/or prognosis of cancer
CA2840149C (en) Methods and nucleic acids for determining the prognosis of a cancer subject
WO2012006447A3 (en) Gene signatures for cancer prognosis
WO2008097466A3 (en) Metastasis specific splice variants of mena and uses thereof in diagnosis, prognosis and treatment of tumors
EP3622087A4 (en) Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
EP2988131A4 (en) Genetic marker for early breast cancer prognosis prediction and diagnosis, and use thereof
IN2012DN01979A (en)
WO2007112350A3 (en) Method of assessing the metastatic status of a primary tumor
WO2011098839A3 (en) Di -aspirin derivatives for use in the treatment of colorectal cancer
WO2013040358A3 (en) Assays and compositions for detection of agr2
WO2009074364A8 (en) Novel prognostic breast cancer marker
WO2009050453A3 (en) Breast cancer associated antigen
WO2012024640A3 (en) Mst1 as a prognostic biomarker and therapeutic target in human cancer

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10819727

Country of ref document: EP

Kind code of ref document: A2